

DOCTORAL THESIS

Development of mass spectrometry-based omics for studying neurometabolic changes associated with exposure of polybrominated diphenyl ethers and its correlation with Parkinson's disease

Ji, Fenfen

Date of Award:
2019

[Link to publication](#)

General rights

Copyright and intellectual property rights for the publications made accessible in HKBU Scholars are retained by the authors and/or other copyright owners. In addition to the restrictions prescribed by the Copyright Ordinance of Hong Kong, all users and readers must also observe the following terms of use:

- Users may download and print one copy of any publication from HKBU Scholars for the purpose of private study or research
- Users cannot further distribute the material or use it for any profit-making activity or commercial gain
- To share publications in HKBU Scholars with others, users are welcome to freely distribute the permanent URL assigned to the publication

ABSTRACT

Polybrominated diphenyl ethers (PBDEs), as one typical persistent organic pollutants (POPs), are widely spread in the environment and pose potential adverse impacts on human health. As a predominant congener of PBDEs, 2,2',4,4'-tetrabromodiphenyl ether (BDE-47) has been reported to affect habituation capability, synaptic plasticity, and vesicular neurotransmitter release. As an important *in vivo* metabolite derived from BDE-47, 6-hydroxy-BDE-47 (6-OH-BDE-47) was also reported as a neurotoxin. However, the possible linkages between BDE-47/6-OH-BDE-47 exposure and typical neurodegenerative diseases such as Parkinson's disease (PD) are still unclear.

Mass spectrometry (MS) based omics integrated with bioinformatics is emerging as a powerful tool to evaluate metabolic changes occurred after different exposures. Here we developed non-targeted metabolomics, lipidomics, and isobaric tag for relative and absolute quantitation (iTRAQ) proteomics methods based on liquid chromatography-mass spectrometry (LC-MS) and gas chromatography-mass spectrometry (GC-MS) to depict BDE-47/6-OH-BDE-47 induced metabolic changes and to explore the possible contribution of their exposure to PD pathology/pathogenesis.

BDE-47 dissolved in corn oil (0, 1, 10 and 100 mg/kg bwt) was orally administered to adult male C57BL/6 mice for 30 consecutive days. Results of global metabolomics and lipidomics studies of PD-related brain regions based on LC-orbitrap MS revealed significant metabolite changes between the exposed and control groups in purine pathway, glutathione pathway, tryptophan pathway, phenylalanine pathway, alanine, aspartate and glutamate pathway, and lipid composition, mainly involved in oxidative stress and neurotransmitter production. By further quantifying metabolites involved in tryptophan and phenylalanine pathways in mice serum, colon and brain samples by using LC-triple quadrupole MS, dysregulation of PD linked neurotransmitters dopamine and serotonin were confirmed. iTRAQ proteomics study of the striatum, the part of the brain that is most intensively studied in PD pathogenesis, revealed that BDE-47 could induce neurotransmitter system disturbance, mitochondrial dysfunction, oxidative stress and abnormal phosphorylation. Oxygen consumption rate after BDE-47 treatment (0, 1 and 10 μ M) in mouse neuroblastoma (N2a) cells was measured for the confirmation. BDE-47 was demonstrated to impair mitochondrial function.

We also investigated whether BDE-47 exposure could worsen PD situation by applying transgenic *Drosophila* (fly) model in which human α -synuclein (α -syn) was overexpressed in wide-type fly to simulate PD. BDE-47 (0, 2, 10 and 50 μ M)

was fed to flies continuously for 30 days. Integrated LC-MS and GC-MS profiling indicated metabolic changes in tryptophan, phenylalanine, purine, and alanine, aspartate and glutamate pathways, similar to those from mouse experiment. After quantified metabolites of interest by LC-triple quadrupole MS, we confirmed the slowed-down formation of KYNA (kynurenic acid, a neuro-protector) and speeded-up formation of 3HKYN (3-hydroxykynurenine, a neurotoxin) in all BDE-47 exposed groups on the 20th exposure day. The levels of SAM/SAH (methylation biomarker) and GSH/GSSG (oxidative stress biomarker) were found to decrease on the 30th exposure day. Collectively, we propose that BDE-47 could induce imbalance of kynurenine metabolism, insufficient methylation and oxidative stress, which might contribute to the PD progression.

To further explore the underlying mechanism of 6-OH-BDE-47 induced neurotoxicity, we conducted omics study of metabolic changes induced by 6-OH-BDE-47 on N2a cells. Cells were exposed to 6-OH-BDE-47 (0, 0.5 and 1 μ M) for 24 hours. Considerable metabolic changes in pyrimidine and purine metabolism were observed in high exposure condition while oxidative stress was appeared under low exposure condition. Moreover, 6-OH-BDE-47 was found to affect the dopamine production. iTRAQ proteomics was carried out and pinpointed the dysregulation of ribosome, proteasome, RNA metabolism,

aminoacyl-tRNA biosynthesis, vesicular trafficking, purine pathway, and mitochondria electron transport. Immunocytochemistry and Western blot analysis further confirmed that 6-OH-BDE-47 could inhibit autophagy flux, which might result in the aberrant protein aggregation, a pathological hallmark of PD.

We further investigated whether 6-OH-BDE-47 exposure could directly induce PD pathology in Sprague Dawley rat. 6-OH-BDE-47 (0.1, 1 and 10 μg) was stereotaxically injected into the right VTA and SNc regions in the midbrain of rat where there are abundant dopaminergic neurons. The apomorphine-induced rotation test indicated significant deterioration in motor function in the group receiving injection of 10 μg . Striatal dopamine was found to decline in a dose-dependent manner. Notably, 6-OH-BDE-47 also promoted the formation of α -syn aggregate, an important pathological hallmark of PD. Proteomics study revealed that protein degradation processes were crucial rather than oxidative stress in 6-OH-BDE-47 induced neurotoxicity *in vivo*. Mechanistic study based on Western blot further confirmed that 6-OH-BDE-47 could inhibit ubiquitination and autophagy. Collectively, the rat experiment demonstrated that 6-OH-BDE-47 administration could induce motor defect by impairing dopaminergic system and promote α -syn aggregation by inhibiting ubiquitination and autophagy, suggesting that 6-OH-BDE-47 could be a novel risk factor of PD.

Table of Contents

DECLARATION	i
ABSTRACT	ii
ACKNOWLEDGEMENTS	vi
Table of Contents	vii
List of Tables	xii
List of Figures	xiv
List of Abbreviations and Symbols	xxi
Chapter 1 Introduction	1
1.1 Metabolomics.....	1
1.1.1 Analytical technology available for non-targeted metabolomics	2
1.1.2 Workflow for non-targeted metabolomics.....	6
1.1.3 Quality control and quality assurance strategy for non-targeted metabolomics	8
1.1.4 Targeted metabolomics.....	10
1.2 High-resolution MS based lipidomics	12
1.3 MS based proteomics.....	14
1.4 Polybrominated diphenyl ethers	20
1.5 Persistent organic pollutants and Parkinson's disease.....	24
1.6 Neuro-metabolic pathways	27
1.7 Study objectives and hypothesis	35

Chapter 2	Integrated metabolomic, lipidomic and proteomic analysis reveals BDE-47 induced Parkinson’s disease-like metabolic changes in C57BL/6 mice	37
2.1	Introduction.....	37
2.2	Material and methods.....	39
2.2.1	Chemicals and reagents	39
2.2.2	Animals and experimental design.....	39
2.2.3	Global metabolomic analysis.....	40
2.2.4	Lipidomic analysis.....	42
2.2.5	Targeted metabolomic analysis	45
2.2.6	iTRAQ-based quantitative proteomic analysis.....	48
2.3	Results and discussion	53
2.3.1	Analytical method development.....	53
2.3.2	Global metabolic changes in serum and different brain parts	57
2.3.3	Lipid changes in brain.....	73
2.3.4	Study of tryptophan and phenylalanine pathway metabolites by targeted metabolomics	79
2.3.5	Protein changes in brain.....	82
2.4	Chapter summary	93
Chapter 3	MS-based metabolomic analysis of the neurometabolic changes associated with BDE-47 exposure in <i>Drosophila</i> model	95
3.1	Introduction.....	95
3.2	Material and Methods	97

3.2.1 Chemicals and reagents	97
3.2.2 Fly experiment	97
3.2.3 Climbing test.....	98
3.2.4 Global metabolomic analysis by LC-MS.....	98
3.2.5 Global metabolomic analysis by GC-MS	99
3.2.6 Targeted metabolomic analysis	101
3.3 Results and discussion	104
3.3.1 BDE-47 induces motor defects	104
3.3.2 Analytical method development	105
3.3.3 Global metabolic changes	109
3.3.4 Study of metabolites in tryptophan, phenylalanine and methionine pathways by targeted metabolomics	113
3.4 Chapter summary	120

**Chapter 4 MS-based metabolomic and proteomic analysis of
6-OH-BDE-47-induced metabolic changes in N2a cell model 121**

4.1 Introduction.....	121
4.2 Material and methods.....	123
4.2.1 Chemicals.....	123
4.2.2 Cell culture and viability assessment.....	123
4.2.3 Global and targeted metabolomic analysis	123
4.2.4 MS-based proteomic analysis (iTRAQ)	124
4.2.5 Chemical proteomics to profile 6-OH-BDE-47 binding kinases.....	125
4.2.6 Immunocytochemistry and Western blot analysis	126
4.2.7 Cell mitochondrial stress test.....	127

4.3 Results and discussion	129
4.3.1 Comparison of cytotoxicity between BDE-47 and 6-OH-BDE-47	129
4.3.2 Metabolome changes induced by 6-OH-BDE-47	130
4.3.3 Proteome changes induced by 6-OH-BDE-47	134
4.3.4 Study of 6-OH-BDE-47 binding kinase.....	139
4.3.5 BDE-47 and 6-OH-BDE-47 inhibit autophagy flux in N2a cells.....	142
4.3.6 BDE-47 impairs mitochondrial function	145
4.4 Chapter summary	147

Chapter 5 Parkinson’s disease pathology induced by 6-OH-BDE-47 in Sprague Dawley rat148

5.1 Introduction.....	148
5.2 Materials and methods	150
5.2.1 Chemicals and reagents	150
5.2.2 Animals.....	150
5.2.3 Stereotaxic infusion of 6-OH-BDE-47 and behavior test.....	150
5.2.4 LC-MS/MS analysis	152
5.2.5 Western blot analysis	155
5.2.6 Quantitative RT-PCR.....	157
5.2.7 MS-based proteomic analysis (iTRAQ)	158
5.2.8 PRM-based targeted proteomic strategy to verify protein targets.....	159
5.2.9 Statistical analysis.....	160
5.3 Results and discussion	162
5.3.1 Stereotaxic infusion of 6-OH-BDE-47 induces motor defects	162

5.3.2 6-OH-BDE-47 disturbs neurotransmitters without causing obvious oxidative stress.....	165
5.3.3 6-OH-BDE-47 promotes α -syn aggregation.....	168
5.3.4 6-OH-BDE-47 impairs protein degradation pathways	170
5.3.5 6-OH-BDE-47 affects ubiquitination and autophagy	176
5.4 Chapter summary	178
Chapter 6 Conclusions and future work	180
List of References.....	183
Outcome of the thesis work.....	209
CURRICULUM VITAE	212